14 July 2021 - The opening of a new multimillion dollar national service to treat neuroendocrine cancer means patients will no longer have to travel across the ditch.
Kiwis requiring Peptide Receptor Radionuclide Therapy, or PRRT, used to be sent to Melbourne for treatment, but travel restrictions as a result of the COVID-19 pandemic has made that difficult.